甲状腺乳头状癌患者临床病理特征和BRAF V600E基因突变对其颈部淋巴结转移的影响

doi:10.13481/j.1671-587X.20220420

Abstract

Abstract:

Objective： To investigate the correlations of cervical lymph node metastasis with the chinicopathological characteristics and BRAF V600E gene mutation in the patients with papillary thyroid cancer （PTC）， and to clarify the influencing factors of cervical lymph nodes metastasis in the patients with PTC.

Methods

The PTC patients underwent surgical therapy in our hospital were selected；the patients’ clinical data were retrospectively analyzed， including age， sex， side， number， metastatic lymph nodes and location of the PTC patients， and the pathologic data were also analyzed， including location， diameter， number， capsular invasion， peri-tumor fibrosis， psammoma bodies， vascular and nervous invasion. The BRAF V600E mutation detection was performed in PTC tissue， the correlation of cervical lymph node metastasis with the clinical characteristics，pothological feateres and BRAF V600E gene mutation of the PTC patients were analyzed，and Logistic regression analysis was performed to analyze the influencing factors of cervical lymph node metastasis in the PTC patients.

Results

In the 321 PTC patients， 129 patients （40.2%） were found with cervical lymph node metastatasis. BRAF V600E gene mutation were found in 279 （86.9%） patients； there was no correlation of BRAF V600E gene mutation with cervical lymph node metastasis in the PTC patients（P>0.05）.Cervical lymph node metastasis had correlations with age， maximal diameter， multiple tumors in bilateral sides， psammoma bodies and vascular invasion（P<0.05 or P<0.01）. The results of Logistic regression analysis demonstrated that age （OR=0.729，95%CI：0.600－0.885）， maximal tumor diameter （OR=1.796，95%CI：1.326－2.433）， tumor number（OR=1.947，95%CI：1.225－3.096），psammoma bodies （OR=2.578，95%CI：1.037－6.409）， and vascular invasions （OR=8.856，95%CI：1.929－40.656） were the influencing factors of cervical lymph node metastasis in the PTC patients.

Conclusion

The cervical lymph node metastasis of the PTC patients shows the correlations with age， maximal tumor diameter， tumor number， psammoma bodies and vascular invasion， and shows no correlation with BRAF V600E gene mutation.

Key words: Papillary thyroid cancer, BRAF V600E, Lymph node, Metastasis

CLC Number:

R736.1

Wei JI,Jian DONG,Hong CHANG,Xuemei DU,Hong PENG,Hong XIE,Aimin ZHAO,Wei YAN,Juan BAI,Zhenxing PENG,Jinshu YIN. Influence of chinicopathological characteristics and BRAF V600E gene mutation in cervical lymph node metastasis in patients with papillary thyroid cancer[J].Journal of Jilin University(Medicine Edition), 2022, 48(4): 995-1002.

Figures/Tables 4

Tab.1

Tab. 2

Tab.3

Tab.4

References 31

1	VACCARELLA S， LORTET-TIEULENT J， COLOMBET M， et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents： a population-based study［J］. Lancet Diabetes Endocrinol， 2021， 9（3）： 144-152.
2	HADDAD R I， NASR C， BISCHOFF L， et al. NCCN guidelines insights： thyroid carcinoma， version 2.2018［J］. J Natl Compr Canc Netw， 2018， 16（12）： 1429-1440.
3	FILETTI S， DURANTE C， HARTL D， et al. Thyroid cancer： ESMO clinical practice guidelines for diagnosis， treatment and follow-up［J］. Ann Oncol， 2019， 30（12）： 1856-1883.
4	CHEN P， PAN L Q， HUANG W S， et al. BRAF V600E and lymph node metastases in papillary thyroid cancer［J］. Endocr Connect， 2020， 9（10）： 999-1008.
5	YU J H， DENG Y H， LIU T T， et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics［J］. Nat Commun， 2020， 11（1）： 4807.
6	IBRAHIMPASIC T， GHOSSEIN R， SHAH J P，et al. Poorly differentiated carcinoma of the thyroid gland： current status and future prospects［J］. Thyroid， 2019， 29（3）： 311-321.
7	AL-MASRI M， AL-SHOBAKI T， AL-NAJJAR H，et al.BRAF V600E mutation in papillary thyroid carcinoma： its relation to clinical features and oncologic outcomes in a single cancer centre experience［J］. Endocr Connect， 2021， 10（12）： 1531-1537.
8	TAO Y B， WANG F， SHEN X P， et al. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer［J］. J Clin Endocrinol Metab， 2021， 106（11）： 3228-3238.
9	SCHEFFEL R S， DE CRISTO A P， ROMITTI M， et al. The BRAF^V600E mutation analysis and risk stratification in papillary thyroid carcinoma［J］. Arch Endocrinol Metab， 2021， 64（6）： 751-757.
10	KIM K J， KIM S G， TAN J， et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma［J］. Eur J Cancer， 2020， 124： 161-169.
11	ZHOU S L， GUO Y P， ZHANG L， et al. Predicting factors of central lymph node metastasis and BRAF^V600E mutation in Chinese population with papillary thyroid carcinoma［J］. World J Surg Oncol， 2021， 19（1）： 211.
12	JI W， XIE H， WEI B J， et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma［J］. Int J Clin Exp Pathol， 2019，12（9）： 3492-3499.
13	XU S Y， HUANG H， QIAN J X， et al. Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes［J］.JAMA Netw Open，2021，4（7）： e2118526.
14	HO A S， LUU M， BARRIOS L， et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma［J］.JAMA Oncol， 2020，6（5）： 706-713.
15	ENUMAH S， FINGERET A， PARANGI S， et al. BRAF^V600E mutation is associated with an increased risk of papillary thyroid cancer recurrence［J］. World J Surg， 2020， 44（8）： 2685-2691.
16	ZURNADZHY L， BOGDANOVA T， ROGOUNOVITCH T I， et al. The BRAF V600E mutation is not a risk factor for more aggressive tumor behavior in radiogenic and sporadic papillary thyroid carcinoma at a young age［J］. Cancers， 2021， 13（23）： 6038.
17	LAN X B， BAO H， GE X Y， et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis［J］. Cancer Sci， 2020， 111（6）： 2163-2173.
18	CHEN T Y， LORCH J H， WONG K S， et al. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma［J］. Histopathology，2020，77（2）： 314-320.
19	O’CONNOR E， MULLINS M， O’CONNOR D，et al. The relationship between ultrasound microcalcifications and psammoma bodies in thyroid tumours： a single-institution retrospective study［J］. Clin Radiol， 2022， 77（1）： e48-e54.
20	SIPPEL R S， ROBBINS S E， POEHLS J L， et al. A randomized controlled clinical trial： no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer［J］. Ann Surg， 2020， 272（3）： 496-503.
21	倪洪岗，杨娟，陈永华，等.甲状腺癌细胞增殖、凋亡、迁移、侵袭的影响及其机制研究［J］. 中国实用内科杂志， 2020， 40（11）： 969.
22	王欣，赵玉珠.促甲状腺激素与甲状腺癌发病及病理特征的关系研究［J］.中国实用内科杂志， 2021， 41（5）： 424-427.
23	SILVER J A， BOGATCHENKO M， PUSZTASZERI M，et al. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm［J］. Le J D’oto Rhino Laryngol De Chir Cervico Faciale， 2021， 50（1）： 63.
24	HERNANDEZ B Y， RAHMAN M， LOO L W M，et al. BRAF V600E， hypothyroidism， and human relaxin in thyroid carcinogenesis［J］. J Cancer Res Clin Oncol， 2021， 147（1）： 183-194.
25	PUCCINI M， MANCA G， NERI C M， et al. Effect of sentinel node biopsy in clinically N0， BRAF V600E-mutated， small papillary thyroid carcinoma： a pilot study［J］. Clin Nucl Med， 2019， 44（5）： 359-364.
26	PESSÔA-PEREIRA D， MEDEIROS M F D S， LIMA V M S，et al.Association between BRAF （V600E） mutation and clinicopathological features of papillary thyroid carcinoma： a Brazilian single-centre case series［J］. Arch Endocrinol Metab， 2019， 63（2）： 97-106.
27	KURE S， ISHINO K， KUDO M， et al. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma： a single-institution experience［J］. J Int Med Res， 2019， 47（11）： 5560-5572.
28	LIU J J， LIU R Y， SHEN X P， et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer［J］. J Nucl Med， 2020， 61（2）： 177-182.
29	SAMÀ M T， GROSSO E， MELE C， et al. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma［J］. Endocrine， 2021， 71（1）： 149-157.
30	DESAI J， GAN H， BARROW C， et al. Phase Ⅰ， open-label， dose-escalation/dose-expansion study of lifirafenib （BGB-283）， an RAF family kinase inhibitor， in patients with solid tumors［J］. J Clin Oncol， 2020， 38（19）： 2140-2150.
31	ANAND D， YASHASHWI K， KUMAR N， et al. Weakly supervised learning on unannotated H&E-stained slides predicts BRAF mutation in thyroid cancer with high accuracy［J］. J Pathol， 2021， 255（3）： 232-242.

Variable	Total (Constituent ratio )	Lymph node metastasis（n=129）	No lymph node metastasis（n=192）	χ2	P
Age (year)				9.834	0.002
<40	150 (46.7)	74 （57.4）	76 （39.6）
≥40	171 (53.3)	55 （42.6）	116 （60.4）
Gender				0.362	0.547
Female	225 (70.1)	88 (68.2)	137 (71.4)
Male	96 (29.9)	41 (31.8)	55 (28.6)
Maximal diameter				15.412	<0.001
<0.5 cm	75 (23.4)	20 （15.5）	55 （28.6）
0.5－1.0 cm	117 (36.4)	41 （31.8）	76 （39.6）
>1.0 cm	129 (40.2)	68 （52.7）	61 （31.8）
Tumor location				8.470	0.014
Single tumor in unilateral lobe	204 (63.6)	70 (54.3)	134 (69.8)
Multiple tumors in unilateral lobe	41 (12.8)	19 (14.7)	22 (11.4)
Multiple tumors in both lobes	76 (23.6)	40 (31.0)	36（18.8）
Capsular invasion				1.479	0.224
Positive	137 (42.7)	54 (41.9)	83 (43.2)
Negative	184 (57.3)	75 (58.1)	109 (56.8)
Psammoma bodies				4.409	0.036
Positive	21 (6.5)	13 (10.1)	8 (4.2)
Negative	300 (93.5)	116 (89.9)	184 (95.8)
Lymph-plasma cells				0.079	0.778
Positive	77 (24.0)	32 (24.8)	45 (23.4)
Negative	244 (76.0)	97 (75.2)	147 (76.6)
Fiber wrapped				1.523	0.217
Positive	114 (35.5)	51 (39.5)	63 (32.8)
Negative	207 (64.5)	78 (60.5)	129 (67.2)
Vascular invasion				11.126	0.001
Positive	13 (4.0)	11 (8.5)	2 (1.0)
Negative	298 (96.0)	118 (91.5)	190 (99.0)
Nerve invasion				0.787	0.375
Positive	8 (2.5)	2 (1.6)	6 (3.1)
Negative	313 (97.5)	127 (98.4)	186 (96.9)
BRAF V600E				0.002	0.967
Positive	279 (86.9)	112 (86.8)	167 (87.0)
Negative	42 (13.1)	17 (13.2)	25 (13.0)

Variable	Total (Constituent ratio)	Single tumor in one lobe	Multiple tumors in one lobe	Multiple tumors in both lobes	χ2	P
Lymph node number					2.782	0.249
<5	82 （63.6）	49 (70.0)	11 (57.9)	22 (55.0)
≥5	47 （36.4）	21 (30.0)	8 (42.1)	18 (45.0)
Lymph node location					16.141	<0.01
One side	104 (80.6)	62 (88.6)	18 (94.7)	24 (60.0)
Both sides	25 (19.4)	8 (11.4)	1 (5.3)	16 (40.0)
Lymph node zone					7.148	0.128
Central zone	76 (58.9)	47 (67.1)	8 (42.1)	21 (52.5)
Lateral zone	11 (8.5)	3 (4.3)	2 (10.5)	6 (15.0)
Both zones	42 (32.6)	20 (28.6)	9 (47.4)	13 (32.5)

Variable		Value
Lymph node metastasis	Y	0=No,1=Yes
Age	X1	1=<30 years，2=30－39 years,3=40－49 years,4=50－59 years,5=>60 years
Multiple tumors in bilateral lobes	X2	0=No,1=yes
Maximal diameter	X3	1=≤0.5 cm,2=0.6－1.0 cm,3=>1.0 cm
Number	X4	1=Single，2=Multiple
Psammoma bodies	X5	0=Negative，1=Positive
Vascular invasion	X6	0=Negative，1=Positive

Variable	β	SE	Wald χ²	P	OR	95%CI
Age	－0.316	0.099	10.152	0.001	0.729	0.600－0.885
Maximal diameter	0.586	0.155	14.325	0.000	1.796	1.326－2.433
Number	0.666	0.237	7.940	0.005	1.947	1.225－3.096
Psammoma bodies	0.947	0.465	4.151	0.042	2.578	1.037－6.409
Vascular invasion	2.181	0.778	7.868	0.005	8.856	1.929－40.656

[1]	Yingran YANG,Jing WANG,Youzheng QIU,Shanshan ZHANG,Na LI,Wei SHEN,Ying CHEN,Ning WANG. Inhibitory effect of IFN-γ on proliferation of neuroblastoma cells and clinical significance of SULT2B1 protein expression in neuroblastoma tissue [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1267-1273.
[2]	Yunxiu XIA,Shuo ZHANG,Huanhai ZHANG,Fei WANG,Hongliang DONG,Jing DU. Long non-coding RNA LINC00973 promotes migration, invasion and distal metastasis of epithelial ovarian cancer and its molecular mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 866-878.
[3]	Changyu SHI,Yong LI,Jing DENG,Chunmei PIAO,Ming JIN. Bioinformatics analysis on adjustment effect of colorectal liver metastases model in mice based on complement alternative pathway and its experimental verification [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 703-715.
[4]	Peng QI,Xianying MENG,Meihua PIAO,Qiang ZHANG. Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1504-1512.
[5]	Chang GAO,Yan LIU,Haoxiang YANG,Cuicui ZHANG. Effect of long non-coding RNA MALAT1 on angiogenesis of human brain microvascular endothelial cells induced by oxygen-glucose deprivation/reoxygenation hypoxic [J]. Journal of Jilin University(Medicine Edition), 2023, 49(4): 832-839.
[6]	Lingyao XU,Shutang WEI,Yong DONG,Zhenglu SUN,Junbo ZHAO,Dazheng HAN. Regulatory effect of lncRNA MALAT1 on activation of hepatic stellate cell and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 697-705.
[7]	Mengshi MA,Peng CHEN,Zhongsen MA. Pulmonary benign metastasizing leiomyoma：A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 203-208.
[8]	Yun LIU,Linqi ZHU,Shihe SHAO. Effects of circular RNA hsa_circ_0009735 on epithelial mesenchymal transformation, cell cycle, and autophagy of gastric cancer cells [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1498-1509.
[9]	Zhihui ZHAO,Xianghua BAI,Jinling HE,Weiqin DUAN,Min LIU,Shengmao ZHANG. Inhibitory effect of sufentanil on apoptosis of myocardial cells in myocardial ischemia-reperfusion injury rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 364-373.
[10]	Rongrong XU,Yuan LU,Jianming ZHOU,Dandan PENG,Xiaoli ZHU,Shuhua HAN. Paraganglioma with pulmonary metastasis: [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 505-512.
[11]	Lisong CHEN,Hui FANG,Hefei WANG,Chengyuan HE,Xiaodong GAI,Chun LI. Effects of Notch1 signaling pathway on invasion and cisplatin resistance of lung adenocarcinoma cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1171-1177.
[12]	Dongkui ZHOU, Mingqian LU, Yaxin LIN, Xuesong FENG, Yan GAO, Hao SONG. Small cell carcinoma of gallbladder with liver and retroperitoneal lymph node metastasis: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 747-752.
[13]	Zishen XIAO,Shuteng DIAO,Lishuang ZHANG,Jie LIU,Lijuan YANG,Xinyu FENG,Zhenjiang WANG,Yanbo LIU. Promotion effect of IL-17A on migration of prostatic cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(6): 1194-1201.
[14]	GUO Weiwei, QIN Yue, YANG Haibo, MI Zhanhu. Promotion effect of LncRNA MALAT1 on osteogenic differentiation of adipose-derived mesenchymal stem cells through miR-34c/SATB2 axis [J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 963-971.
[15]	WANG Yu, JIANG Xinping, CHANG Jian, QU Chao, HAN Dongbing. ALK-positive anaplastic large cell lymphoma with changes in skin mucosal lymph nodes as first symptom: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1432-1435.

Influence of chinicopathological characteristics and BRAF V600E gene mutation in cervical lymph node metastasis in patients with papillary thyroid cancer

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 31

Related Articles 15

Metrics

Comments

Recommended 10